Výsledky vyhledávání - "Thomas H. Cartwright"

Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity

Autor: Michael K. Bamat, Thomas R. King, Thomas H. Cartwright, Bassel F. El-Rayes, Reid von Borstel, Wen Wee Ma, Marwan Fakih, James Posey, Muhammad Wasif Saif

Publikováno v: Cancer. 123:345-356

BACKGROUND Increased susceptibility to 5-fluorouracil (5-FU)/capecitabine can lead to rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, and other genetic variations in the enzymes that metabolize 5-F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edc2b1ab0c1e1ff4406731896c076b6b
https://doi.org/10.1002/cncr.30321

Zobrazit plný text záznamu

Treatment Patterns and Economic Assessment of Systemic Therapy for Metastatic Colorectal Cancer

Autor: L. Wen, Patricia S. Fox, Ed Wang, Robyn K. Harrell, Thomas H. Cartwright, Janet L. Espirito

Publikováno v: Journal of Cancer Therapy. :646-655

Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths in the United States. The goal of this study was to understand treatment patterns, biomarker testing practices, treatment a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37b71ab5bbd16ed91e556a7597a3b6df
https://doi.org/10.4236/jct.2016.79067

Zobrazit plný text záznamu

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Autor: Ian Chau, Eduardo Polo Marques, Ana Ruíz Casado, Pilar García-Alfonso, Marina Celanovic, Pascaline Picard, Thomas H. Cartwright, Marwan Fakih, Zdenĕk Linke

Publikováno v: Cancers
Volume 12
Issue 3
Cancers, Vol 12, Iss 3, p 657 (2020)

For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. This prospective, observational, noncomparative, post-authorization safety s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5efeb76d9fa3e16db4dce7d98162c8d7
https://doi.org/10.3390/cancers12030657

Zobrazit plný text záznamu

Plný text ve formátu HTML

Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE

Autor: Eduardo Polo Marques, Zdenĕk Linke, Ana Ruíz Casado, Pilar García-Alfonso, Ian Chau, Pascaline Picard, Arvind Rup Singh, Marwan Fakih, Thomas H. Cartwright, Taylor Salinardi, Marina Celanovic

Publikováno v: Journal of Clinical Oncology. 38:212-212

212 Background: Anti-EGFR therapies are frequently given as first-line therapy for patients with mCRC, while anti-angiogenic therapies may be suitable at any line. Despite improving outcomes for patients with mCRC, there is still an unmet need regard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47b6415eb64763b90018648af36218fd
https://doi.org/10.1200/jco.2020.38.4_suppl.212

Zobrazit plný text záznamu

Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting

Autor: Monika Parisi, Thomas H. Cartwright, Thomas Wilson, Manish Patel, Janet L. Espirito, Corey Pelletier, Hani M. Babiker

Publikováno v: Drugs-Real World Outcomes

Background The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p + G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with gemcitabine monotherapy in clinical trials for metastatic pancreatic cancer; h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f00cc49b95ec27105aa48fc8629c17a
https://pubmed.ncbi.nlm.nih.gov/29946913

Zobrazit plný text záznamu

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non–Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care

Autor: Fred Schreiber, Philip Sharp, Mokenge P. Malafa, Richard Brown, Merry Jennifer Markham, Guillermo Abesada-Terk, Ji-Hyun Lee, Paul B. Jacobsen, Douglas Faig, Thomas H. Cartwright, Richard M. Levine, Carlos Alemany, Tawee Tanvetyanon, William J. Fulp, George P. Kim

Publikováno v: Journal of Oncology Practice. 11:332-337

For patients with resected non-small-cell lung cancer, national guidelines recommend cisplatin-based doublet chemotherapy as the preferred treatment. However, many patients receive a carboplatin-based regimen instead. We aimed to identify factors ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c48fd941d6b48dc4f91648c154aa8314
https://doi.org/10.1200/jop.2014.001750

Zobrazit plný text záznamu

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials

Autor: Muhammad Wasif Saif, H.-J. Schmoll, Steve Lee, Edward McKenna, Michael O’Connell, Thomas H. Cartwright, Greg Yothers, Daniel G. Haller, Chris Twelves, Weijing Sun

Publikováno v: Annals of Oncology. 26:715-724

Adjuvant oxaliplatin plus capecitabine or leucovorin/5-fluorouracil (LV/5-FU) (XELOX/FOLFOX) is the standard of care for stage III colon cancer (CC); however, there is disagreement regarding oxaliplatin benefit in patients aged70. In most analyses, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d80444bc5a4bc3fc281bbdbd110d21
https://doi.org/10.1093/annonc/mdv003

Zobrazit plný text záznamu

Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses

Autor: Marwan Fakih, P. García-Alfonso, Thomas H. Cartwright, E Polo Marques, A. Ruiz-Casado, Pascaline Picard, Zdenĕk Linke, Ian Chau, Marina Celanovic

Publikováno v: Annals of Oncology. 30:v227

Background For patients with mCRC that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. In these secondary analyses of the OZONE study, aflibercept + FOLFIRI safety and efficacy was ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f57d150cd241204b48992553c6f0088
https://doi.org/10.1093/annonc/mdz246.079

Zobrazit plný text záznamu

Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management

Autor: Thomas H. Cartwright

Publikováno v: Clinical Colorectal Cancer. 12:86-94

Colorectal cancer (CRC) is the third most common cancer in men and women, and, despite advances in detection and treatment that result in a steadily decreasing incidence and mortality, remains a leading cause of death. The 5-year survival rate of per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e5550ee0bc5fac34efc335d87516b8
https://doi.org/10.1016/j.clcc.2012.12.001

Zobrazit plný text záznamu

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

Autor: Donald A. Richards, Terrence P. Cescon, John T. Hamm, Thomas A. Rado, Brad Rosbrook, Thomas H. Cartwright, Allen Lee Cohn, Jamal Tarazi, Jeffrey R. Infante, Sinil Kim, Philip J. McGee, William Jeffery Edenfield, Imtiaz Malik, Tony R. Reid

Publikováno v: Cancer. 119:2555-2563

BACKGROUND In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3db1bbf8e67467fc73587b98d0d2f469
https://doi.org/10.1002/cncr.28112

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání